Labiotech.eu

Sickle Cell Disease Modus Therapeutics Cover

News and Trends 16 Jul 2018

Series A Boost for Swedish Biotech’s Sickle Cell Disease Treatment

Modus Therapeutics closed SEK 140M (€13.5M) in Series A financing to complete a Phase II study testing its sickle cell disease drug and to prepare for further clinical trials. The financing round was led by HealthCap, a European venture capital firm focused on life science investments, which will contribute SEK 60M (€5.8M). The remaining funds […]

July 16, 2018 - 3 minutesmins - By Alexander Burik

Flow State Francis Crick Institute Alex May

More News! 14 Jul 2018

An Artist’s Insight into the Day-to-Day Life at the Francis Crick Institute

A new interactive art installation at the Francis Crick Institute in London lets visitors peek into what life at the famous research institute is like. “The Francis Crick Institute is this incredible, huge, imposing building of which the public can see very little inside,” Alex May, a British digital artist, told me during an interview. His […]

July 14, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Jul 2018

French Biotech Raises €12.5M for Antibiotic Booster Drugs

French-biotech Antabio closed €12.5M at series A to fund its pipeline of antibiotic booster drugs that should help in the global fight against antimicrobial resistance. After raising €7.3M last year, Antabio extended its Series A financing round with €5.2M of additional funding raised from private investors. The French biotech will use the funding to continue […]

July 13, 2018 - 2 minutesmins - By Alexander Burik

In Depth 12 Jul 2018

How Plant Biotechnology Can Give Us Better Food and Medicines

From super crops to better medicines, biotechnology from plants could make a big difference in our lives. Here’s how. What have plants ever done for us? Well, a colossal amount of things. Throughout human history, they have fed us, made medicinal compounds, given us clothes, produced oxygen and much more. However, what if there were […]

July 12, 2018 - 4 minutesmins - By Jonathan Smith

News and Trends 12 Jul 2018

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) for each product. Genmab has a market cap of €60Bn ($70Bn). The funding will be […]

July 12, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 11 Jul 2018

Radioactive Nanoparticle Could Improve Cancer Diagnoses

Isotopia Molecular Imaging, an Israeli company, is developing a radioactive marker made of gold nanoparticles to detect cancer more accurately than with current diagnostic tools. PET and CT scans are two types of X-ray tests that use small quantities of radioactive materials, called contrast agents, to help visualize and assess organ and tissue function. These […]

July 11, 2018 - 2 minutesmins - By Alexander Burik

Expert Advice 11 Jul 2018

How Successful Life Science Businesses Generate Their Leads with “White Paper Marketing”

The life science sector is full of ambitious professionals who are both overwhelmingly busy and voracious learners. This presents a problem and an opportunity. If you can employ educational marketing to your market, leaving your readers significantly more informed on an important issue than before they found you, you can position yourself as a […]

July 11, 2018 - 9 minutesmins - By James Mathison

Retinitis pigmentosa gene therapy Horama

News and Trends 11 Jul 2018

Gene Therapy for Retinitis Pigmentosa Tested in Humans for the First Time

French biotech Horama has treated the first patients with a gene therapy for retinitis pigmentosa that could prevent the progressive loss of vision caused by this genetic condition. A Phase I/II trial with Horama’s gene therapy for retinitis pigmentosa is running at the Nantes University Hospital. The therapy is aimed at fixing genetic defects in a […]

July 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Jul 2018

Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial

BioArctic, based in Stockholm, has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial tested the antibody in 856 patients with early-stage Alzheimer’s disease with plaques of amyloid-beta protein in their brains, which is considered a common hallmark of the disease. Results taken at […]

July 9, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 9 Jul 2018

Abingworth Closes €268M to Invest in Life Science Companies

Abingworth has closed $315M (€268M) for its most recent fund, Abingworth Bioventures VII, which invests in European and US life science companies. In the current fundraising, Abingworth surpassed its target of $300M. The new fund will invest in life science companies in all stages of development, including early and late-stage venture deals. The company plans to […]

July 9, 2018 - 2 minutesmins - By Alexander Burik

science gallery dublin life at the edges biology in space

More News! 8 Jul 2018

How Can Biology Help Us Prepare For Life in Space?

An exhibition at the Science Gallery Dublin explores how humans are preparing to live in the harsh conditions of outer space — and how microorganisms might help us do so. Space traveling is closer than many of us think. NASA has plans to send humans to Mars in the 2030s, and Elon Musk seems to […]

July 8, 2018 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jul 2018

A New HIV Vaccine Could Protect Patients Against Multiple Viral Strains

A new HIV vaccine is moving into a Phase IIb trial and could potentially protect patients against multiple HIV strains worldwide. Recent findings from a Phase I/IIa trial published in The Lancet show that a new HIV-1 vaccine was safe and produced an immune response against HIV 393 healthy adults, as well as in a […]

July 6, 2018 - 2 minutesmins - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us